Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/<i>neu-</i>targeted Therapy

Abstract

NIR imaging with HER2-specific imaging probes enables evaluation of the therapeutic susceptibility of human mammary tumors and of drug dosing during HER2-targeted therapy with trastuzumab. This approach, combined with tomographic imaging techniques, has potential in the clinical setting for determining patient eligibility for and adequate drug dosing in molecularly targeted cancer therapies.